上海醫藥(02607.HK)旗下鹽酸胺碘酮注射液獲內地批准生產

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

上海醫藥(02607.HK)旗下鹽酸胺碘酮注射液獲內地批准生產

阿思達克 03-22 09:08

上海醫藥(02607.HK)(601607.SH)公布，其下屬全資子公司上藥第一生化的鹽酸胺碘酮注射液收到國家藥監局頒發的《藥品註冊證書》(證書編號：2024S00255)，該藥品獲得批准生產。鹽酸胺碘酮注射液主要用於治療不宜口服給藥時嚴重的心律失常，最早由賽諾菲研發，於1976年在法國上市。2022年1月上藥第一生化就該藥品向國家藥監局提出註冊上市申請並獲受理。截至目前，公司針對該藥品已投入研發費用約720萬元人民幣。

上海醫藥(02607.HK)

Relevant Stocks

上海醫藥(02607.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

上海醫藥(02607.HK)旗下鹽酸胺碘酮注射液獲內地批准生產

Services

About Us

Agreement Statement